WO1994012165A3 - Enzyme inhibitors - Google Patents
Enzyme inhibitors Download PDFInfo
- Publication number
- WO1994012165A3 WO1994012165A3 PCT/GB1993/002437 GB9302437W WO9412165A3 WO 1994012165 A3 WO1994012165 A3 WO 1994012165A3 GB 9302437 W GB9302437 W GB 9302437W WO 9412165 A3 WO9412165 A3 WO 9412165A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- enzyme inhibitors
- medicine
- processes
- advantage
- preparation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/30—Isothioureas
- C07C335/32—Isothioureas having sulfur atoms of isothiourea groups bound to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/18—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94900266A EP0670720A1 (en) | 1992-11-27 | 1993-11-26 | Enzyme inhibitors |
JP6512923A JPH08503940A (en) | 1992-11-27 | 1993-11-26 | Enzyme inhibitors |
AU55330/94A AU5533094A (en) | 1992-11-27 | 1993-11-26 | Enzyme inhibitors |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929224948A GB9224948D0 (en) | 1992-11-27 | 1992-11-27 | Nitric oxide synthase inhibitors |
GB9224948.1 | 1992-11-27 | ||
GB9315159.5 | 1993-07-22 | ||
GB939315159A GB9315159D0 (en) | 1993-07-22 | 1993-07-22 | Nitric oxide synthase inhibitors |
GB939319663A GB9319663D0 (en) | 1993-09-23 | 1993-09-23 | Enzyme inhibitors |
GB9319663.2 | 1993-09-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1994012165A2 WO1994012165A2 (en) | 1994-06-09 |
WO1994012165A3 true WO1994012165A3 (en) | 1994-12-08 |
Family
ID=27266488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/002437 WO1994012165A2 (en) | 1992-11-27 | 1993-11-26 | Enzyme inhibitors |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0670720A1 (en) |
JP (1) | JPH08503940A (en) |
CN (1) | CN1095710A (en) |
AU (1) | AU5533094A (en) |
IL (1) | IL107771A0 (en) |
SI (1) | SI9300616A (en) |
WO (1) | WO1994012165A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
US8895548B2 (en) | 2007-04-24 | 2014-11-25 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating alzheimer's disease |
US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
US9273053B2 (en) | 2008-06-13 | 2016-03-01 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity |
US9290466B2 (en) | 2009-12-11 | 2016-03-22 | Shionogi & Co., Ltd. | Oxazine derivatives |
US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5807885A (en) * | 1993-08-12 | 1998-09-15 | Astra Aktiebolag | Amidine derivatives with nitric oxide synthetase activities |
RU2136661C1 (en) * | 1993-10-21 | 1999-09-10 | Джи Ди Сирл энд Ко. | Amidino-derivatives, their use and pharmaceutical composition |
AU682768B2 (en) * | 1994-05-07 | 1997-10-16 | Astra Aktiebolag | Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase |
GB9418912D0 (en) * | 1994-09-20 | 1994-11-09 | Fisons Corp | Pharmaceutically active compounds |
AU4149696A (en) * | 1994-11-15 | 1996-06-06 | Merck & Co., Inc. | Substituted heterocycles as inhibitors of nitric oxide synthase |
WO1996018617A1 (en) * | 1994-12-12 | 1996-06-20 | Merck & Co., Inc. | Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase |
JPH08333258A (en) | 1994-12-14 | 1996-12-17 | Japan Tobacco Inc | Thiazine or thiazepine derivative and nitrogen monoxide synthetase inhibitor containing the compound |
FR2728261A1 (en) * | 1994-12-14 | 1996-06-21 | Japan Tobacco Inc | THIAZINE OR THIAZEPINE DERIVATIVES USEFUL AS INHIBITORS OF NO-SYNTHETASE |
DE4444930A1 (en) * | 1994-12-16 | 1996-06-27 | Cassella Ag | 2-amino-1,3-thiazepines and their use as inhibitors of nitric oxide synthase |
WO1996021445A1 (en) * | 1995-01-13 | 1996-07-18 | The General Hospital Corporation | Methods of inhibiting neurodegenerative diseases |
TW397812B (en) * | 1995-02-11 | 2000-07-11 | Astra Ab | Bicyclic isothiourea derivatives useful in therapy |
FR2730733B1 (en) * | 1995-02-17 | 1997-07-04 | Hoechst Lab | NOVEL SULFUR NITROETHYLENIC DERIVATIVES AND THEIR APPLICATIONS AS NO-SYNTHASE INHIBITORS |
US5929063A (en) * | 1995-03-24 | 1999-07-27 | Children's Hospital Medical Center | Mercapto and seleno derivatives as inhibitors of nitric oxide synthase |
US5674907A (en) * | 1995-03-24 | 1997-10-07 | Children's Hospital Medical Center | Mercapto derivatives as inhibitors of nitric oxide synthase |
GB9506188D0 (en) * | 1995-03-27 | 1995-05-17 | Fujisawa Pharmaceutical Co | Amidine derivatives |
WO1996033175A1 (en) * | 1995-04-20 | 1996-10-24 | G.D. Searle & Co. | Cyclic amidino agents useful as nitric oxide synthase inhibitors |
US5908842A (en) * | 1995-12-08 | 1999-06-01 | Merck & Co., Inc. | Substituted 2-acylamino-pyridines as inhibitors of nitric oxide synthase |
US5945408A (en) * | 1996-03-06 | 1999-08-31 | G.D. Searle & Co. | Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors |
US6160000A (en) * | 1996-12-23 | 2000-12-12 | Merck & Co., Inc. | Antidiabetic agents based on aryl and heteroarylacetic acids |
US6090839A (en) * | 1996-12-23 | 2000-07-18 | Merck & Co., Inc. | Antidiabetic agents |
US5981556A (en) * | 1997-07-22 | 1999-11-09 | G.D. Searle & Co. | 1,3-diazolino and 1,3-diazolidino heterocycles as useful nitric oxide synthase inhibitors |
US6673807B1 (en) * | 1998-04-06 | 2004-01-06 | Fujisawa Pharmaceutical Co., Ltd. | Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cyclosporins |
US6552052B2 (en) | 1998-06-10 | 2003-04-22 | Monsanto/G.D. Searle | Pyrrolo[2,1-c][1,2,4] thiadiazoles and Pyrollo[2,1-c][1,12,4]oxadiazoles useful as nitric oxide synthase inhibitors |
US6489323B1 (en) | 1998-06-10 | 2002-12-03 | G.D. Searle & Co. | Heterobicyclic and tricyclic nitric oxide synthase inhibitors |
GB9903404D0 (en) | 1999-02-16 | 1999-04-07 | Angiogene Pharm Ltd | Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis |
EE05082B1 (en) * | 2000-01-19 | 2008-10-15 | Cadila Healthcare Ltd. | A Pyrrole Line Compound, its Preparation and Use in the Formulation of a Lipid and Cholesterol Lowering Drug, and a Pharmaceutical Composition Containing it |
AU2001247745B2 (en) | 2000-03-24 | 2006-08-31 | Pharmacia Corporation | Amidino compounds useful as nitric oxide synthase inhibitors |
US7087633B2 (en) | 2000-03-31 | 2006-08-08 | Universitair Medisch Centrum | Method for treating perinatal asphyxia in a human or animal neonate |
ATE296627T1 (en) | 2000-03-31 | 2005-06-15 | Univ Medisch Centrum Utrecht | USE OF 2-IMINOBIOTIN FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE PREVENTION AND/OR THERAPY OF COMPLICATIONS IN NEWBORN BABY DURING BIRTH |
AR030416A1 (en) | 2000-04-13 | 2003-08-20 | Pharmacia Corp | HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-3,4, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS AN INHIBITOR OF SYNTHETIC NITRIC OXIDE |
US6545170B2 (en) | 2000-04-13 | 2003-04-08 | Pharmacia Corporation | 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
AR032318A1 (en) | 2000-04-13 | 2003-11-05 | Pharmacia Corp | HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-5,6; PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE IN THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT AS AN INHIBITOR OF NITRICAL SYNTHEASE OXIDE |
US6956131B2 (en) | 2000-04-13 | 2005-10-18 | Pharmacia Corporation | 2-amino-3, 4 heptenoic compounds useful as nitric oxide synthase inhibitors |
AR034120A1 (en) | 2000-04-13 | 2004-02-04 | Pharmacia Corp | HALOGENATED DERIVATIVE COMPOUND OF HEPTENOIC ACID 2-AMINO-4,5, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND THE USE OF SUCH COMPOUND AND SUCH COMPOSITION IN THE MANUFACTURE OF A MEDICINAL PRODUCT TO INHIBIT OR MODULATE NITRIC ACID SYNTHESIS |
US6787668B2 (en) | 2000-04-13 | 2004-09-07 | Pharmacia Corporation | 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors |
US6420566B2 (en) | 2000-06-09 | 2002-07-16 | Aventis Pharma S.A. | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof |
FR2810037B1 (en) * | 2000-06-09 | 2004-04-23 | Aventis Pharma Sa | USE OF 2-AMINOTHIAZOLINE DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS |
FR2832152A1 (en) * | 2001-11-09 | 2003-05-16 | Aventis Pharma Sa | New 2-amino-thiazoline derivatives having inducible NO-synthase inhibiting activity, useful for treating Parkinson's, cerebral disorders, migraines, depression, diabetes |
FR2810036B1 (en) * | 2000-06-09 | 2004-04-23 | Aventis Pharma Sa | 4,5-DIHYDRO-1,3-THIAZOL-2-YLAMINE DERIVATIVES, THEIR PREPARATION AND THE PHAMARCEUTICAL COMPOSITIONS CONTAINING THEM |
US6451821B1 (en) | 2000-06-09 | 2002-09-17 | Aventis Pharma S.A. | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase |
US6344473B1 (en) | 2000-08-07 | 2002-02-05 | G.D. Searle & Co. | Imidazoles useful as nitric oxide synthase inhibitors |
US7012098B2 (en) | 2001-03-23 | 2006-03-14 | Pharmacia Corporation | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers |
FR2832150B1 (en) * | 2001-11-09 | 2004-07-16 | Aventis Pharma Sa | USE OF 2-AMINO-4-PYRIDYLMETHYL-THIAZOLINE DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS |
FR2832151B1 (en) * | 2001-11-09 | 2004-12-17 | Aventis Pharma Sa | USE OF 2-AMINO-4-HETEROARYLETHYL-THIAZOLINE DERIVATIVES AS INDUCTIBLE NO-SYNTHASE INHIBITORS |
BR0206354A (en) * | 2001-11-09 | 2003-12-23 | Aventis Pharma Sa | Use of 2-amino thiazoline derivatives as inducibly inducible synthase inhibitors |
MXPA04003766A (en) * | 2001-11-09 | 2004-07-29 | Aventis Pharma Sa | 2-amino-4-heteroarylethyl thiazoline derivatives and their use an inhibitors of inducible no-synthase. |
IL161843A0 (en) | 2001-11-09 | 2005-11-20 | Aventis Pharma Sa | Use of 2-amino-4-pyridylmethyl-thiazoline dervatives as inhibitors of inducible no-synthase |
ES2537898T3 (en) | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Aminothiazolidine and aminotetrahydrotiazepine derivatives as BACE 1 inhibitors |
WO2007108004A2 (en) * | 2006-03-23 | 2007-09-27 | Meditor Pharmaceuticals Ltd. | S-alkylisothiouronium derivatives for the treatment of inflammatory diseases |
JP5383484B2 (en) | 2007-04-24 | 2014-01-08 | 塩野義製薬株式会社 | Aminodihydrothiazine derivatives substituted with cyclic groups |
CN101372471B (en) * | 2008-10-08 | 2010-12-22 | 中国科学院化学研究所 | Novel use of alkyl isourea compound and analogues thereof |
JPWO2010047372A1 (en) | 2008-10-22 | 2012-03-22 | 塩野義製薬株式会社 | 2-Aminopyrimidin-4-one and 2-aminopyridine derivatives having BACE1 inhibitory activity |
US20120015961A1 (en) | 2009-03-31 | 2012-01-19 | Shionogi & Co., Ltd. | Isothiourea derivatives or isourea derivatives having bace1 inhibitory activity |
JP5816630B2 (en) | 2010-10-29 | 2015-11-18 | 塩野義製薬株式会社 | Naphthyridine derivatives |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1178242A (en) * | 1966-02-05 | 1970-01-21 | Wellcome Found | Novel Biologically Active Bis-Isothioureas |
DE2317106A1 (en) * | 1972-04-06 | 1973-10-11 | Uniroyal Inc | 2- (3-BENZO SQUARE CLAMP ON SQUARE CLAMP TO THENYL) -2-THIOPSEUDO UREA AND ITS PHARMACEUTICAL SALTS AND THESE MEDICINAL PREPARATIONS |
US3954982A (en) * | 1972-04-20 | 1976-05-04 | Smith Kline & French Laboratories Limited | Pharmaceutical compositions and method of inhibiting H-1 and H-2 histamine receptors |
US4126670A (en) * | 1976-03-29 | 1978-11-21 | Smith Kline & French Laboratories Limited | Method of stimulating histamine H2 -receptors |
US4208430A (en) * | 1979-03-15 | 1980-06-17 | Smithkline Corporation | Pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase |
US4262125A (en) * | 1979-07-23 | 1981-04-14 | American Home Products Corporation | (1H-Imidazol-5-ylmethyl)isothioureas |
EP0245669A2 (en) * | 1986-05-14 | 1987-11-19 | Medopharm Arzneimittelwerk Dr. Zillich GmbH & Co. | Pharmaceutical preparation for preventing damage to living cells by free radicals, or for increasing the efficacy of organic sulphur compounds, and process for increasing the life span of isolated organs |
EP0420396A2 (en) * | 1989-07-25 | 1991-04-03 | Smith Kline & French Laboratories Limited | Imidazole derivatives as histamine H3-agonists |
WO1991004037A1 (en) * | 1989-09-19 | 1991-04-04 | Jan Kristoffer Hellstrand | Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists |
EP0547558A1 (en) * | 1991-12-16 | 1993-06-23 | Washington University | Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation |
US7759999B2 (en) * | 2007-11-09 | 2010-07-20 | Hynix Semiconductor Inc. | Externally asynchronous internally clocked system |
-
1993
- 1993-11-26 IL IL10777193A patent/IL107771A0/en unknown
- 1993-11-26 WO PCT/GB1993/002437 patent/WO1994012165A2/en not_active Application Discontinuation
- 1993-11-26 SI SI9300616A patent/SI9300616A/en unknown
- 1993-11-26 JP JP6512923A patent/JPH08503940A/en active Pending
- 1993-11-26 CN CN93121643A patent/CN1095710A/en active Pending
- 1993-11-26 AU AU55330/94A patent/AU5533094A/en not_active Abandoned
- 1993-11-26 EP EP94900266A patent/EP0670720A1/en not_active Withdrawn
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1178242A (en) * | 1966-02-05 | 1970-01-21 | Wellcome Found | Novel Biologically Active Bis-Isothioureas |
DE2317106A1 (en) * | 1972-04-06 | 1973-10-11 | Uniroyal Inc | 2- (3-BENZO SQUARE CLAMP ON SQUARE CLAMP TO THENYL) -2-THIOPSEUDO UREA AND ITS PHARMACEUTICAL SALTS AND THESE MEDICINAL PREPARATIONS |
US3790600A (en) * | 1972-04-06 | 1974-02-05 | Uniroyal Inc | 2-(3-benzo(b)thenyl)-2-thiopseudourea and its pharmaceutically acceptable salts |
US3954982A (en) * | 1972-04-20 | 1976-05-04 | Smith Kline & French Laboratories Limited | Pharmaceutical compositions and method of inhibiting H-1 and H-2 histamine receptors |
US4126670A (en) * | 1976-03-29 | 1978-11-21 | Smith Kline & French Laboratories Limited | Method of stimulating histamine H2 -receptors |
US4208430A (en) * | 1979-03-15 | 1980-06-17 | Smithkline Corporation | Pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase |
US4262125A (en) * | 1979-07-23 | 1981-04-14 | American Home Products Corporation | (1H-Imidazol-5-ylmethyl)isothioureas |
EP0245669A2 (en) * | 1986-05-14 | 1987-11-19 | Medopharm Arzneimittelwerk Dr. Zillich GmbH & Co. | Pharmaceutical preparation for preventing damage to living cells by free radicals, or for increasing the efficacy of organic sulphur compounds, and process for increasing the life span of isolated organs |
EP0420396A2 (en) * | 1989-07-25 | 1991-04-03 | Smith Kline & French Laboratories Limited | Imidazole derivatives as histamine H3-agonists |
WO1991004037A1 (en) * | 1989-09-19 | 1991-04-04 | Jan Kristoffer Hellstrand | Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists |
EP0547558A1 (en) * | 1991-12-16 | 1993-06-23 | Washington University | Use of aminoguanidine for the manufacture of a medicament for inhibiting nitric oxide formation |
US7759999B2 (en) * | 2007-11-09 | 2010-07-20 | Hynix Semiconductor Inc. | Externally asynchronous internally clocked system |
Non-Patent Citations (22)
Title |
---|
"accession number 04916379", DIALOG INFORMATION SERVICES, FILE 155: MEDLINE * |
"accession number 05268819", DIALOG INFORMATION SERVICES, FILE 155: MEDLINE * |
"accession number 05837693", DIALOG INFORMATION SERVICES, FILE 155: MEDLINE * |
"accession number 08184588", DIALOG INFORMATION SERVICES, FILE 155: MEDLINE * |
"The Merck Index, 11th Edition", MERCK & CO., INC., RAHWAY, N.J., U.S.A. * |
B.MALINOWSKA ET AL.: "Identification of endothelial H1, vascular H2 and cardiac presynaptic H3 receptors in the pithed rat", NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., vol. 347, no. 1, January 1993 (1993-01-01), pages 55 - 60 * |
DATABASE WPI Derwent World Patents Index; AN 92-259284 * |
E.E.J.HAAKSMA ET AL.: "A theoretical study concerning the mode of interaction of the histamine H2-agonist dimaprit", J.MOL.GRAPH., vol. 10, no. 2, June 1992 (1992-06-01), pages 79 - 87 * |
G.A.FECHNER ET AL.: "ANTIPROLIFERATIVE AND DEPIGMENTING EFFECTS OF THE HISTAMINE (H2) AGONIST DIMAPRIT AND ITS DERIVATIVES ON HUMAN MELANOMA CELLS", BIOCHEM. PHARMACOL., vol. 43, no. 10, 28 May 1992 (1992-05-28), pages 2083 - 2090, XP025542111, DOI: doi:10.1016/0006-2952(92)90165-F * |
G.J.DURANT ET AL.: "Dimaprit, [S-[3-(N,N-dimethylamino)propyl]isothiourea], A Highly Specific Histamine H2-Receptor Agonist. Part 2. Structure-Activity Considerations", AGENTS ACTIONS, vol. 7, no. 1, March 1977 (1977-03-01), pages 39 - 43 * |
G.J.STERK ET AL.: "The influence of guanidino and isothiourea groups in histaminergic compounds on H2-activity", AGENTS ACTIONS, vol. 18, no. 1-2, April 1986 (1986-04-01), pages 137 - 140 * |
I.R.KATZ ET AL., INT. IMMUNOL., vol. 4, no. 2, February 1992 (1992-02-01), pages 183 - 190 * |
J.L.ORTIZ ET AL.: "Histamine Receptors on Human Isolated Pulmonary Arterial Muscle Preparations: Effects of Endothelial Cell Removal and Nitric Oxide Inhibitors", J.PHARMACOL.EXP.THER., vol. 260, no. 2, February 1992 (1992-02-01), pages 762 - 767 * |
K.NAGARAJAN ET AL.: "Structure Activity Relations among Cyclic & Acyclic S-(3-Indolyl)isothioureas - Development of a Potent Vasoconstrictor, Tinazole, 3-(2-Imidazolin-2-yl-thio)indole", INDIAN J. EXP. BIOL., vol. 19, no. 12, December 1981 (1981-12-01), pages 1150 - 1153, XP009064573 * |
L.BEAULIEU ET AL., INT. ARCH. ALLERGY APPL. IMMUNOL., vol. 79, no. 3, 1986, pages 249 - 252 * |
M.KELM ET AL.: "Mechanisms of Histamine-Induced Coronary Vasodilation: H1-Receptor-Mediated Release of Endothelium-Derived Nitric Oxide", J.VASC.RES., vol. 30, no. 3, May 1993 (1993-05-01), pages 132 - 138 * |
M.R.VICKERS ET AL., AGENTS ACTIONS, vol. 12, December 1982 (1982-12-01), pages 691 - 698 * |
R.GANELLIN: "Medicinal Chemistry and Dynamic Structure-Activity Analysis in the Discovery of Drugs Acting at Histamine H2 Receptors", J.MED.CHEM., vol. 24, no. 8, August 1981 (1981-08-01), pages 913 - 920 * |
S.A.SELEZNEV ET AL., PATOL. FIZIOL. EKSP. TER., no. 1, January 1984 (1984-01-01), pages 41 - 45 * |
S.B.FLYNN ET AL.: "THE CARDIOVASCULAR RESPONSE TO DIMAPRIT, A SELECTIVE HISTAMINE H2-RECEPTOR AGONIST", BR.J.PHARMACOL., vol. 61, no. 1, September 1977 (1977-09-01), pages 101 - 107 * |
S.FRENCH ET AL.: "Modulation of in vitro Cellular Immune Response by Histamine Agonists or Antagonists in Murine Species", ARZNEIMITTELFORSCHUNG, vol. 35, no. 1A, 1985, pages 390 - 394 * |
T.HIRAYAMA ET AL.: "Anti-tumor Activities of Some Heterocyclic and Nitrogen-containing Compounds", YAKUGAKU ZASSHI, vol. 100, no. 12, 1980, pages 1225 - 1234 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8895548B2 (en) | 2007-04-24 | 2014-11-25 | Shionogi & Co., Ltd. | Pharmaceutical composition for treating alzheimer's disease |
US9273053B2 (en) | 2008-06-13 | 2016-03-01 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having Beta secretase inhibitory activity |
US9290466B2 (en) | 2009-12-11 | 2016-03-22 | Shionogi & Co., Ltd. | Oxazine derivatives |
US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
US8883779B2 (en) | 2011-04-26 | 2014-11-11 | Shinogi & Co., Ltd. | Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them |
US9540359B2 (en) | 2012-10-24 | 2017-01-10 | Shionogi & Co., Ltd. | Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity |
Also Published As
Publication number | Publication date |
---|---|
SI9300616A (en) | 1994-06-30 |
WO1994012165A2 (en) | 1994-06-09 |
AU5533094A (en) | 1994-06-22 |
JPH08503940A (en) | 1996-04-30 |
IL107771A0 (en) | 1994-02-27 |
CN1095710A (en) | 1994-11-30 |
EP0670720A1 (en) | 1995-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994012165A3 (en) | Enzyme inhibitors | |
WO1995009619A3 (en) | Substituted urea and isothiourea derivatives as no synthase inhibitors | |
HUP0004421A3 (en) | Urea derivatives and pharmaceutical compositions containing them, use thereof for the treatment of deseases mediated by impdh enzyme | |
CA2250372A1 (en) | 6-phenylpyridyl-2-amine derivatives | |
HUP0001170A3 (en) | Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer | |
AU6194894A (en) | Bile acid derivatives, processes for their preparation and the use of these compounds as medicaments | |
GEP20012442B (en) | Irreversible Inhibitors of Tyrosine Kinases | |
CA2148928A1 (en) | Pharmacologically active pyridine derivatives and processes for the preparation thereof | |
AU2746695A (en) | Metalloproteinase inhibitors | |
AU1819088A (en) | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | |
CA2193337A1 (en) | 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds as pharmaceutical active ingredients | |
IL91307A0 (en) | Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them | |
AU1061988A (en) | Phosphinothricin-resistance gene active in plants, and its use | |
EP1210941A3 (en) | Pharmaceutical compositions containing ritonavir (ABT-538) in combination with indinavir (MK-639) and their use for treating AIDS | |
SK4395A3 (en) | Parathormone derivatives, method of their production and pharmaceutical preparations containing this derivatives | |
AU1992592A (en) | Treatment of drug withdrawal symptoms and drug craving with type b monoamine oxidase inhibitors | |
DE3070189D1 (en) | Medicament, particularly for the treatment of cholera, and pharmaceutical compositions containing it | |
AU3734999A (en) | Use of rosmarinic acid and derivatives thereof as an immunosuppressant or an inhibitor of sh2-mediated process | |
EP0678031A4 (en) | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof. | |
AU5015396A (en) | Thiazole and thiadiazole derivatives, their preparation and pharmaceutical compositions useful in the treatment of throm bocytopenia | |
AU6351186A (en) | Pharmaceutical composition comprising 1-hydroxy-2-pyridone and method for the treatment of acne | |
AU1209995A (en) | Use of nitric oxide synthase inhibitors in the treatment of autoimmune diseases | |
PL312908A1 (en) | Drugs for treating aids and/or hiv infections, containing composition consisting of quinoxalin and protease inhibitors | |
AU2807689A (en) | Method for the treatment of body tissues and the administration of drugs thereto | |
AU8449591A (en) | Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994900266 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1995 436465 Date of ref document: 19950719 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1994900266 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994900266 Country of ref document: EP |